Anji Biotech

About Us

Anji Biotech

Peptide field
R&D projects
Patents filed

Founded in April 2012, Nanjing Anji Biotech Co., Ltd. is a biotech company focused on the research and development of innovative peptide drugs. It is located in Hongfeng Science & Technology Park of the National Nanjing Economic and Technological Development Zone. The company has been certified as a National High-tech Enterprise for four consecutive terms since 2015.

The company has always been committed to the development of original innovative peptide drugs, creating differentiated products driven by clinical and patient needs. It currently has more than 10 peptide drug pipelines under development, some of which are about to enter Phase II clinical trials, along with over a hundred reserve candidate peptide molecules spanning fields such as rheumatoid arthritis, oncology, pain, fibrosis, AMD and anti-aging. It has filed 210 invention patents in China and abroad, 90 of which have been granted.

Technology

High-throughput novel target and micropeptide discovery technology, and structure-targeted peptide computer-aided design technology (STP-CADD).

Corporate Culture

Digital healthcare and the globe

Management Team

Advisory Team

Milestones

2012
2012

Anji Biotech was incorporated in Nanjing

2013
2013

Antianjipeptide obtained a Class 1.1 new drug clinical trial approval

2015
2015

Saisheng Pharmaceutical acquired the HM-3 clinical trial approval

2016
2016

Establishment of the STP-CADD platform

2018
2018

Pegylated Antianjipeptide obtained clinical trial approval

Establishment of the micropeptide discovery platform

2020
2020

Angel round (Huae Investment)

2022
2022

Pre-A round (Xingang High-tech Investment)

2025
2025

US$453M license agreement with Amphastar (North America)